Literature DB >> 20427692

Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Louis M Luttrell1, Diane Gesty-Palmer.   

Abstract

Heptahelical G protein-coupled receptors are the most diverse and therapeutically important family of receptors in the human genome. Ligand binding activates heterotrimeric G proteins that transmit intracellular signals by regulating effector enzymes or ion channels. G protein signaling is terminated, in large part, by arrestin binding, which uncouples the receptor and G protein and targets the receptor for internalization. It is clear, however, that heptahelical receptor signaling does not end with desensitization. Arrestins bind a host of catalytically active proteins and serve as ligand-regulated scaffolds that recruit protein and lipid kinase, phosphatase, phosphodiesterase, and ubiquitin ligase activity into the receptor-arrestin complex. Although many of these arrestin-bound effectors serve to modulate G protein signaling, degrading second messengers and regulating endocytosis and trafficking, other signals seem to extend beyond the receptor-arrestin complex to regulate such processes as protein translation and gene transcription. Although these findings have led to a re-envisioning of heptahelical receptor signaling, little is known about the physiological roles of arrestin-dependent signaling. In vivo, the duality of arrestin function makes it difficult to dissociate the consequences of arrestin-dependent desensitization from those that might be ascribed to arrestin-mediated signaling. Nonetheless, recent evidence generated using arrestin knockouts, G protein-uncoupled receptor mutants, and arrestin pathway-selective "biased agonists" is beginning to reveal that arrestin signaling plays important roles in the retina, central nervous system, cardiovascular system, bone remodeling, immune system, and cancer. Understanding the signaling roles of arrestins may foster the development of pathway-selective drugs that exploit these pathways for therapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427692      PMCID: PMC2879915          DOI: 10.1124/pr.109.002436

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  223 in total

Review 1.  Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function.

Authors:  Stephane Angers; Ali Salahpour; Michel Bouvier
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

2.  The role of a conserved region of the second intracellular loop in AT1 angiotensin receptor activation and signaling.

Authors:  Zsuzsanna Gáborik; Gowraganahalli Jagadeesh; Meng Zhang; András Spät; Kevin J Catt; László Hunyady
Journal:  Endocrinology       Date:  2003-06       Impact factor: 4.736

3.  c-Src-mediated phosphorylation of AP-2 reveals a general mechanism for receptors internalizing through the clathrin pathway.

Authors:  Brandon Zimmerman; May Simaan; Mi-Hye Lee; Louis M Luttrell; Stéphane A Laporte
Journal:  Cell Signal       Date:  2008-10-01       Impact factor: 4.315

4.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

5.  Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors.

Authors:  T J Gardella; M D Luck; G S Jensen; E Schipani; J T Potts; H Jüppner
Journal:  Endocrinology       Date:  1996-09       Impact factor: 4.736

6.  Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells.

Authors:  Noriyuki Sonoda; Takeshi Imamura; Takeshi Yoshizaki; Jennie L Babendure; Juu-Chin Lu; Jerrold M Olefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-29       Impact factor: 11.205

7.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.

Authors:  Robert Fredriksson; Malin C Lagerström; Lars-Gustav Lundin; Helgi B Schiöth
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

8.  Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration.

Authors:  Jihee Kim; Lisheng Zhang; Karsten Peppel; Jiao-Hui Wu; David A Zidar; Leigh Brian; Scott M DeWire; Sabrina T Exum; Robert J Lefkowitz; Neil J Freedman
Journal:  Circ Res       Date:  2008-06-02       Impact factor: 17.367

Review 9.  Parathyroid hormone: a double-edged sword for bone metabolism.

Authors:  Ling Qin; Liza J Raggatt; Nicola C Partridge
Journal:  Trends Endocrinol Metab       Date:  2004-03       Impact factor: 12.015

10.  Beta-arrestin-mediated localization of smoothened to the primary cilium.

Authors:  Jeffrey J Kovacs; Erin J Whalen; Renshui Liu; Kunhong Xiao; Jihee Kim; Minyong Chen; Jiangbo Wang; Wei Chen; Robert J Lefkowitz
Journal:  Science       Date:  2008-05-22       Impact factor: 47.728

View more
  172 in total

Review 1.  Evidence for a functional intracellular angiotensin system in the proximal tubule of the kidney.

Authors:  Brianne Ellis; Xiao C Li; Elisa Miguel-Qin; Victor Gu; Jia L Zhuo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

Review 2.  Regulation of β-adrenergic receptor function: an emphasis on receptor resensitization.

Authors:  Neelakantan T Vasudevan; Maradumane L Mohan; Shyamal K Goswami; Sathyamangla V Naga Prasad
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

3.  A holistic view of GPCR signaling.

Authors:  Terry Kenakin
Journal:  Nat Biotechnol       Date:  2010-09       Impact factor: 54.908

Review 4.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

5.  Orthosteric, Allosteric and Biased Signalling at the Relaxin-3 Receptor RXFP3.

Authors:  Martina Kocan; Sheng Yu Ang; Roger J Summers
Journal:  Neurochem Res       Date:  2015-08-21       Impact factor: 3.996

6.  A G Protein-biased Designer G Protein-coupled Receptor Useful for Studying the Physiological Relevance of Gq/11-dependent Signaling Pathways.

Authors:  Jianxin Hu; Matthew Stern; Luis E Gimenez; Lizzy Wanka; Lu Zhu; Mario Rossi; Jaroslawna Meister; Asuka Inoue; Annette G Beck-Sickinger; Vsevolod V Gurevich; Jürgen Wess
Journal:  J Biol Chem       Date:  2016-02-05       Impact factor: 5.157

Review 7.  MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.

Authors:  Jose C García-Borrón; Zalfa Abdel-Malek; Celia Jiménez-Cervantes
Journal:  Pigment Cell Melanoma Res       Date:  2014-05-30       Impact factor: 4.693

Review 8.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

9.  Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells.

Authors:  Ze Liu; Mandi M Hopkins; Zhihong Zhang; Chrystal B Quisenberry; Louise C Fix; Brianna M Galvan; Kathryn E Meier
Journal:  J Pharmacol Exp Ther       Date:  2014-12-09       Impact factor: 4.030

10.  Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms.

Authors:  Ashley Bathgate-Siryk; Samalia Dabul; Krunal Pandya; Karlee Walklett; Giuseppe Rengo; Alessandro Cannavo; Claudio De Lucia; Daniela Liccardo; Erhe Gao; Dario Leosco; Walter J Koch; Anastasios Lymperopoulos
Journal:  Hypertension       Date:  2013-11-11       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.